anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Total hip arthroplasty (THA) is the operation of choice for salvage of post-traumatic arthritis following acetabular fracture. While high failure rates have been reported for these procedures, existing literature reports mainly on historical implant designs and techniques. We aimed to describe implant survivorships, complications, radiographic results, and clinical outcomes of contemporary THA following prior open reduction internal fixation (ORIF) of an acetabular fracture.
METHODS: We identified 104 patients undergoing THA following prior ORIF of an acetabular fracture from 2000 to 2015 via our institutional total joint registry. Mean age at THA was 50 years (range, 18 to 79 years), 71% were men, and mean body mass index was 27 (range, 18 to 52). All patients were implanted with uncemented acetabular components, and 89% had uncemented stems. Some hardware from prior fixation was retained in 94% of cases. Mean follow-up was 10 years (range, 2 to 21 years).
RESULTS: The 10-year survivorships free of any revision and any reoperation were 98% and 97%, respectively. There were 4 revisions: 1 each for psoas tendonitis, dislocation, acetabular aseptic loosening, and periprosthetic joint infection. There were 9 complications that did not lead to reoperation: 5 dislocations, 2 periprosthetic femur fractures, 1 sciatic nerve palsy, and 1 case of symptomatic heterotopic ossification. All unrevised components appeared radiographically well-fixed. Mean Harris Hip Score improved from mean 50 preoperatively to mean 82 at 5 years (P < .001).
CONCLUSIONS: In this series of contemporary THAs following prior acetabular fracture ORIF, revision-free survivorship was excellent with only a single case of acetabular aseptic loosening. These results are encouraging and suggest that contemporary implants and techniques have notably improved on historic results.
LEVEL OF EVIDENCE: Therapeutic, Level IV.
The invention relates to an article for daily use, namely a slow-release multipurpose drug fragrant pillow, which comprises a pillowcase and a filler, and is characterized in that: the inside of the pillowcase is provided with a balloon which is enclosed by airtight elastic fabric and can be compressed and bounced, the balloon is provided with a filling opening, the balloon is externally connected with an air pipe, and the air pipe is provided with a switch. The beneficial effects are that: a plurality of spices or Chinese herbal medicines can be put into the saccule. At ordinary times, the switch is closed, and the smell of the Chinese herbal medicine cannot be output. When the switch is turned on, especially when the pillow case is under pressure, the saccule is compressed, and the odor of the Chinese herbal medicine flows out in a large amount for people to breathe. When the pressure is released, the balloon springs open to enter air. Thereby controlling the output quantity of the effective components, enhancing the health care effect and prolonging the effective period of the pillow. The health care pillow has the advantages of being capable of being used for adjusting various sub-health states such as insomnia, cervical vertebra discomfort, rhinitis and cardiovascular and cerebrovascular blocking, being simple in structure, low in cost and convenient to use, and being expected to be a necessary product on a living room bed.
In this prospective, randomized controlled 3-month study, 185 post-menopausal women who were diagnosed with osteoporosis and followed up in our outpatient clinic based on the osteoporosis diagnostic criteria by the World Health Organization were analyzed.According to the inclusion and exclusion criteria, 60 patients were included in the study.

The patients included in the study were randomized by the co-researcher into 3 groups of 20 patients each according to the random numbers table. Group 1 received WBV and infrared therapy for 20 minutes per session, 2 days a week for 3 months. Group 2 received only infrared therapy for 20 minutes, 2 days a week for 3 months, in the same bed system. The patients were placed in the supine position with the whole body in contact with the platform/bed during the treatment. In terms of compliance with the WBV therapy, the frequency was increased to 30 Hz in the first week, 40 Hz in the second week, 50 Hz in the third week, and 60 Hz in the fourth week and administered for a total of 20 minutes. Subsequent sessions continued with 60 Hz. The acceleration value administered by the device was 2.0-4.0 m/s², and the amplitude of the applied vibration in the vertical direction was 0.5-2.0 mm.Infrared therapy at a wavelength of 550-950 nm was applied to both groups of patients by means of infrared pads on the bed during the treatment.Group 3 did not receive any treatment. Patients in all 3 groups continued their treatment with 1000 mg Ca and 880 IU vitamin D. The patients were called every week by phone to check whether they were complying with the treatment or not.Bone mineral density (BMD) of the lumbar and femoral regions of all the patients was measured using dual energy x-ray absorptiometry. In addition, osteocalcin and hydroxyproline values were measured. Quality of life was assessed using the Short Form-36 questionnaire, pain was assessed using the visual analog scale, and balance was assessed based on the participants' performance in the Berg Balance test.The scales were applied at the beginning and at the end of the treatment.
A novel receptor-type protein tyrosine phosphatase-? (RPTP?) protein or glycoprotein and the DNA coding therefor is expressed in a wide variety of mammalian tissues. The RPTP? protein or glycoprotein may be produced by recombinant means. Antibodies to the protein, methods for measuring the quantity of the protein, methods for screening compounds, such as drugs, which can bind to the protein and inhibit or stimulate their enzymatic activity, are provided. Further, methods for inhibiting homophilic binding of Type II RPTP, especially RPTP? molecules are provided.
Breast cancer patients have many problems from different treatment processes and care needs to be met. Determining and supporting care needs affects the quality of life of patients. It is known that training provided by mobile applications enables patients with breast cancer to cope easily with their problems and increase their quality of life. Health needs to be individualized by shifting from institution- and physician-centered understanding to individual-centered healthcare service provision. There is no study in the literature evaluating the results of the training given specific to the supportive care needs with mobile application after surgery. The use of the mobile application that allows patient-centered supportive care for the education given to the patients reveals the difference of this study as it also includes interactive training. Mobile application to be created from educational content for patients with breast cancer; It aims to meet the holistic health care needs of women and to increase the quality of life by determining the individual care needs of women in the period after BCS. In this context, it is thought that the aim of reducing the care needs of patients and increasing the quality of life can be achieved with the education given to the patients. The mobile application includes maintaining and improving the health of women with breast cancer and offering solutions based on the literature for the problems they experience. It will be determined what the unmet needs of women with breast cancer that arise in different treatment processes, to what extent this process affects the quality of life of women and what solutions can be offered for these needs. In addition, the advantages and disadvantages of the mobile application method will be determined, and its effect on the patients' supportive care needs and quality of life will be revealed. The findings to be obtained, besides contributing to the literature, will reveal the educational needs of women with breast cancer and guide the treatment and care practices aimed at improving the quality of life. In addition, we aim to contribute to the development of mobile applications in the field of health by sharing our experiences with mobile application preparation. The mobile application developed after the study will be made available to all women with breast cancer.
FIELD: medicine, pharmacy, pharmaceutical technology. SUBSTANCE: composition consists of risperidone-containing microcapsules, polymeric matrix and suitable pharmaceutical carrier. Microcapsules are prepared by dissolution of polymeric material in organic solvent and the following dissolution of active component in solution prepared followed by mixture dispersing in an aqueous medium and immersion of dispersion obtained into cooling liquid and drying microcapsules made. The proposed compositions release an active substance for more prolonged time at the rate that is necessary for curative action manifestation. EFFECT: improved method of making, improved properties of capsules. 13 cl, 1 tbl, 1 dwg, 4 ex
For a total of 9 weeks, patients will be randomized to 9 stimulation frequency and pulse-width setting combinations. The patient will stay with these settings for a week at a time. Prior to the patient's first office visit, he/she will be asked to take a chest x-ray. The patient will also repeat this chest x-ray at the end of the study. Each patient will be asked to provide daily information regarding pain medication usage, spinal cord stimulation usage, amplitude settings, and pain ratings. Additionally, patients will fill out the Multidimensional Pain Inventory (MPI) and the McGill Pain Questionnaire (MPQ) every Monday when they come to the office, before he/she is randomized to the new settings for the week. The patient will also receive a call from the research assistant to see how he/she is doing that week and the patient will be provided with all the pertinent contact information to call at any time to ask questions. The patient can withdraw from the study completely at any point or drop out of the settings for the week. The patient will have a follow-up visit a month from the study's end date to discuss how the patient has been managing his/her pain at his/her spinal cord stimulator settings. Each patient will be compensated for completing the study. Efficacy will be measured based on the patient's answers to the pain probes, device usage, and medication usage.
TIKOSYN is contraindicated in patients with congenital or acquired long QT syndromes. TIKOSYN should not be used in patients with a baseline QT interval or QTc >440 msec (500 msec in patients with ventricular conduction abnormalities). TIKOSYN is also contraindicated in patients with severe renal impairment (calculated creatinine clearance <20 mL/min).

The concomitant use of verapamil or the cation transport system inhibitors cimetidine, trimethoprim (alone or in combination with sulfamethoxazole), or ketoconazole with TIKOSYN is contraindicated (see WARNINGS and PRECAUTIONS, Drug-Drug Interactions), as each of these drugs cause a substantial increase in dofetilide plasma concentrations. In addition, other known inhibitors of the renal cation transport system such as prochlorperazine, dolutegravir and megestrol should not be used in patients on TIKOSYN.

The concomitant use of hydrochlorothiazide (alone or in combinations such as with triamterene) with TIKOSYN is contraindicated (see PRECAUTIONS, Drug-Drug Interactions) because this has been shown to significantly increase dofetilide plasma concentrations and QT interval prolongation.

TIKOSYN is also contraindicated in patients with a known hypersensitivity to the drug.
The present invention relates to the use of an extract of Boehmeria nivea for treating liver cancer. The herb Boehmeria nivea was extracted by Acetone first. Then the liquid-liquid extraction method was used step by step with solvents (n-hexane, ethyl ester, n-butanol) to obtain herbal extracting liquids. And the herbal extracting liquids were condensed to obtain the herbal extracts separately. The herbs extracts were estimated their anticancer activities by HEPG2 Cell line. Each extract was demonstrated its effect of decreasing proliferation of the liver cancer.
The present application relates to the use of helium-oxygen gas mixtures for treating and/or preventing primary and secondary forms of pulmonary hypertension (PH) and to the combination of pharmaceutical drugs with helium-oxygen gas mixtures, wherein the gas mixtures serve as carrier gases for improving the incorporation of a drug for treating and/or preventing pulmonary hypertension. The present application relates to the use of helium-oxygen gas mixtures for treating and/or preventing primary and secondary forms of pulmonary hypertension (PH) and to the combination of pharmaceutical drugs with helium-oxygen gas mixtures, wherein the gas mixtures serve as carrier gases for improving the incorporation of a drug for treating and/or preventing pulmonary hypertension. An optical module is used to guide an EUV radiation beam. The optical module has a chamber (32) that can be evacuated and at least one mirror accommodated in the chamber (32). The mirror has a plurality of individual mirrors (27), the reflective surfaces (34) of which complement each other to form an overall mirror reflective surface. A supporting structure (36) is mechanically connected to a mirror body (35) of the respective individual mirror (27) via a thermally conductive section (37). At least some of the mirror bodies (35) have an associated actuator (50) for the predefined displacement of the mirror body (35) relative to the supporting structure (36) in at least one degree of freedom. The thermally conductive sections (37) are designed to remove a thermal power density of at least 1 kW/m<sup>2</sup> absorbed by the mirror bodies (35) to the supporting structure (36). In one aspect of the optical module, an integrated electronic displacement circuit is associated with each of the displaceable individual mirrors (27) in spatial proximity. In this variant, a central control unit has a signal connection to the integrated electronic displacement circuits of the displaceable individual mirrors (27). The result is an optical module with which lighting optics can be produced which ensure a high EUV radiation throughput even with a non-negligible thermal load on the individual mirrors.
PURPOSE: A cosmetic composition containing a Paeonia suffruticosa Andrews extract and an Albizzia julibrissin Duraz. extract having anti-aging effect is provided. Therefore, the composition has excellent skin elasticity-enhancing effect, antioxidant effect, hyaluronase inhibiting effect, product stability and safety to the skin. CONSTITUTION: An anti-aging cosmetic composition contains a Paeonia suffruticosa Andrews extract and an Albizzia julibrissin Duraz. extract in a ratio of 1:0.001 to 1:20. The extract of Paeonia suffruticosa Andrews and Albizzia julibrissin Duraz. is obtained by extracting in conventional solvents, preferably a mixture of C1-4 anhydrous or hydrous lower alcohol, propylene glycol and distilled water in a ratio of 2:1:1 at 60 to 85deg.C for 5 to 7hr. The use of two herbal extracts having effective anti-aging and antioxidant effects exhibits a synergistic prevention effect on skin aging.
Oral

Adult: The usual adult oral dosage is 2 to 3 tablespoonfuls (30 to 45 mL, containing 20 g to 30 g of lactulose) three or four times daily. The dosage may be adjusted every day or two to produce 2 or 3 soft stools daily.

Hourly doses of 30 to 45 mL of lactulose solution may be used to induce the rapid laxation indicated in the initial phase of the therapy of portal-systemic encephalopathy. When the laxative effect has been achieved, the dose of lactulose may then be reduced to the recommended daily dose. Improvement in the patient’s condition may occur within 24 hours but may not begin before 48 hours or even later.

Continuous long-term therapy is indicated to lessen the severity and prevent the recurrence of portal-systemic encephalopathy. The dose of lactulose for this purpose is the same as the recommended daily dose.

Pediatric: Very little information on the use of lactulose in young children and adolescents has been recorded. As with adults, the subjective goal in proper treatment is to produce 2 or 3 soft stools daily. On the basis of information available, the recommended initial daily oral dose in infants is 2.5 to 10 mL in divided doses. For older children and adolescents the total daily dose is 40 to 90 mL. If the initial dose causes diarrhea, the dose should be reduced immediately. If diarrhea persists, lactulose should be discontinued.

Rectal

When the adult patient is in the impending coma or coma stage of portal-systemic encephalopathy and the danger of aspiration exists, or when the necessary endoscopic or intubation procedures physically interfere with the administration of the recommended oral doses, lactulose solution may be given as a retention enema via a rectal balloon catheter. Cleansing enemas containing soap suds or other alkaline agents should not be used.

Three hundred mL of lactulose solution should be mixed with 700 mL of water or physiologic saline and retained for 30 to 60 minutes. Lactulose enema may be repeated every 4 to 6 hours. If this Lactulose enema is inadvertently evacuated too promptly, it may be repeated immediately.

The goal of treatment is reversal of the coma stage in order that the patient may be able to take oral medication. Reversal of coma may take place within 2 hours of the first enema in some patients. Lactulose given orally in the recommended doses should be started before lactulose by enema is stopped entirely.
To provide a spatial infection risk determination system, a spatial infection risk determination method and a program for preventing infection disease from spreading.SOLUTION: A spatial infection risk determination system 1 comprises a computer 10, an imaging device 20 and a display device 30. A person detection part 101 automatically identifies and detects a person in a video obtained from a video acquisition part 201. An information acquisition part 102 acquires information on properties and a state of a person, or environmental conditions of a space for setting a social distance. An infection risk determination part 103 determines an infection risk based upon the properties and state of the person, or the environmental conditions of the space acquired by the information acquisition part 102. A social distance range calculation part 104 calculates a social distance range based upon the infection risk determined by the infection risk determination part 103. A spatial risk determination part 105 makes a determination based upon the floor area of the space where an infection risk in one space is to be determined and a social distance range of a person present in the space.SELECTED DRAWING: Figure 2
BACKGROUND: Genetic mutations have been reported in a number of bone disorders with or without extra-skeletal manifestations. The purpose of the present study was to investigate the genetic cause in a middle-aged woman with osteoporosis, recurrent fractures and extraskeletal manifestations.
METHODS: A 56-year-old Indian woman presented to the clinic with complaints of difficulty in walking, recurrent fractures, limb bending, progressive skeletal deformities, and poor overall health. At the age of 37, she had experienced severe anemia with diarrhea, significant weight loss, knuckle pigmentation, and a significant loss of scalp hair. She had received multiple blood transfusions and parenteral iron supplementation with normalization of hemoglobin. Subsequently, she had premature menopause at the age of 37. She died at the age of 61 due to liver failure. Exome sequencing followed by Sanger sequencing were undertaken to identify the potential pathogenic mutations.
RESULTS: Genetic investigation identified likely pathogenic mutations in the LRP5 and LGR4 genes. Out of the two mutations, the heterozygous mutation (c.1199C>T) in the LRP5 gene resulted in a non-synonymous substitution of alanine with valine at the 400th position, and the second mutation (c.1403A>C) in the LGR4 gene led to a non-synonymous substitution of tyrosine with serine at the 468th residue of the protein. The minor allele frequencies of the c.1199C>T (LRP5) substitution in the 1000 genomes and IndiGenomes databases are 0.0003 and 0.001, while the c.1403A>C (LGR4) substitution has not been reported in these databases. Various in silico prediction tools suggested LGR4 mutation to be pathogenic and LRP5 mutation to be likely pathogenic.
CONCLUSION: Heterozygous mutations in the LRP5 and LGR4 genes had additive deteriorative effects on BMD, resulting in recurrent fractures and bone deformities, and extended the effect to extraskeletal sites, contributing to the poor overall health in this patient.
This group will not receive a prescribed amount of free fruits and vegetables (F\&V) for 12 weeks. They will serve as the control group. After 12 weeks of control and data comparisons, they will be given 12 weeks of vouchers with minimal contact.
The purpose of this study is to determine the effect of 3 types of sensory-targeted rehabilitation interventions on subjective and objective measures of function for those with chronic ankle instability. If a potential participant is deemed eligible for participation and consents to participate, he/she undergo a pretest session in which balance, gait, and range of motion will be assessed. The participant will then be randomized into one of the 4 treatment groups and undergo the first treatment which takes approximately 5 minutes. After completion of the first treatment, the participant will be immediately retested on the balance, gait, and range of motion measures. Upon completion of testing on the first day, participants in the treatment groups will be asked to return for 5 more treatments over the course of 2 weeks. Upon completion of the treatments, each participant will be tested on their balance, gait, and range of motion again. Then, after 1 month, each participant will be contacted to do a self-reported function follow-up visit in which he/she will be asked to report how stable and functional his/her ankle has been over the past month.
The modified ketogenic diet (MKD) will be applied to participants assigned to the intervention arm for 12 weeks. This group will be evaluated for primary and secondary outcome variables at visits (weeks 0-4-8-12).
The primary aim of this study is to determine the neuroprotective effect of intravenous administration of autologous cord blood in neonates with severe encephalopathy (hypoxic ischemic encephalopathy or cerebral infarction). It is hypothesized that the administration of autologous cord blood will be safe and well tolerated in neonates with severe encephalopathy. If a neonate is born with signs of moderate to severe encephalopathy and cooled for the encephalopathy, the neonate will receive their own cord blood. The cord blood cells are divided into 3 doses and infused at 24, 48, and 72 hours after the birth. Infants will be randomised to treatment with autologous cord blood and hypothermia or hypothermia only and followed for safety and neurodevelopmental outcome up to 18 months. All infants in both groups will be treated with hypothermia for 72 hours started within 6 hours of delivery and infants who allocated to hypothermia and xenon will also receive autologous cord blood in 24 hours from birth through a purpose designed delivery system. Additionally, postnatal neuro-developmental outcomes in neonates with encephalopathy after autologous cord blood therapy will be measured; HIE injury to the neonate/infant brain post autologous cord blood therapy by imaging will be characterized; MRI's will be obtained per clinical routine; serum levels of selected cytokine and neurotrophic factors in neonates with HIE before and after autologous cord blood therapy will be compared and immune cell phenotype and function in neonates with HIE before and after autologous cord blood therapy will be compared.